Enliven Therapeutics (ELVN) Competitors $17.90 -0.94 (-4.99%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$17.90 +0.01 (+0.03%) As of 08/7/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN vs. VKTX, MTSR, SWTX, SRRK, MLTX, PTGX, AAPG, HCM, INDV, and APLSShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Viking Therapeutics (VKTX), Metsera (MTSR), SpringWorks Therapeutics (SWTX), Scholar Rock (SRRK), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), HUTCHMED (HCM), Indivior (INDV), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Enliven Therapeutics vs. Its Competitors Viking Therapeutics Metsera SpringWorks Therapeutics Scholar Rock MoonLake Immunotherapeutics Protagonist Therapeutics Ascentage Pharma Group International HUTCHMED Indivior Apellis Pharmaceuticals Viking Therapeutics (NASDAQ:VKTX) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment. Which has more volatility and risk, VKTX or ELVN? Viking Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Which has better earnings and valuation, VKTX or ELVN? Viking Therapeutics is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$109.96M-$1.53-23.24Enliven TherapeuticsN/AN/A-$89.02M-$1.92-9.32 Is VKTX or ELVN more profitable? Viking Therapeutics' return on equity of -19.98% beat Enliven Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -19.98% -19.38% Enliven Therapeutics N/A -31.84%-30.09% Do analysts recommend VKTX or ELVN? Viking Therapeutics presently has a consensus price target of $86.92, indicating a potential upside of 144.44%. Enliven Therapeutics has a consensus price target of $41.20, indicating a potential upside of 130.17%. Given Viking Therapeutics' higher possible upside, research analysts clearly believe Viking Therapeutics is more favorable than Enliven Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer VKTX or ELVN? In the previous week, Viking Therapeutics had 10 more articles in the media than Enliven Therapeutics. MarketBeat recorded 14 mentions for Viking Therapeutics and 4 mentions for Enliven Therapeutics. Viking Therapeutics' average media sentiment score of 1.28 beat Enliven Therapeutics' score of 1.22 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 12 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in VKTX or ELVN? 76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 4.1% of Viking Therapeutics shares are owned by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryViking Therapeutics beats Enliven Therapeutics on 8 of the 13 factors compared between the two stocks. Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$924.47M$2.51B$5.48B$9.57BDividend YieldN/A1.78%3.99%4.17%P/E Ratio-9.3219.6629.8925.14Price / SalesN/A634.78421.4486.79Price / CashN/A165.0335.9458.58Price / Book2.824.198.125.59Net Income-$89.02M$31.61M$3.26B$265.48M7 Day Performance-4.43%0.95%0.69%1.22%1 Month Performance-10.19%2.90%2.48%0.39%1 Year Performance-17.59%4.11%27.93%23.47% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics2.7537 of 5 stars$17.90-5.0%$41.20+130.2%-17.4%$924.47MN/A-9.3250Positive NewsUpcoming EarningsVKTXViking Therapeutics4.0066 of 5 stars$33.98+4.0%$86.92+155.8%-30.1%$3.67BN/A-22.2120MTSRMetseraN/A$34.44-1.3%$55.00+59.7%N/A$3.67BN/A0.0081SWTXSpringWorks Therapeutics0.3711 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230SRRKScholar Rock4.5522 of 5 stars$36.99+1.7%$44.14+19.3%+280.6%$3.45B$33.19M-14.62140News CoveragePositive NewsEarnings ReportAnalyst ForecastMLTXMoonLake Immunotherapeutics2.6926 of 5 stars$53.32+0.8%$73.14+37.2%+20.5%$3.39BN/A-23.182Earnings ReportAnalyst ForecastAnalyst RevisionPTGXProtagonist Therapeutics2.9632 of 5 stars$53.83flat$66.10+22.8%+42.4%$3.34B$434.43M71.77120Earnings ReportAnalyst ForecastAAPGAscentage Pharma Group InternationalN/A$37.60+1.1%N/AN/A$3.25B$134.35M0.00600Gap UpHCMHUTCHMED2.6468 of 5 stars$17.28+0.1%$28.00+62.0%-16.9%$3.01B$630.20M0.001,811News CoveragePositive NewsINDVIndivior1.5666 of 5 stars$21.22+0.8%$17.75-16.4%+66.8%$2.90B$1.17B34.231,051Analyst ForecastAPLSApellis Pharmaceuticals4.7057 of 5 stars$24.26+5.7%$36.83+51.8%-27.6%$2.90B$781.37M-13.33770 Related Companies and Tools Related Companies Viking Therapeutics Competitors Metsera Competitors SpringWorks Therapeutics Competitors Scholar Rock Competitors MoonLake Immunotherapeutics Competitors Protagonist Therapeutics Competitors Ascentage Pharma Group International Competitors HUTCHMED Competitors Indivior Competitors Apellis Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELVN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
